What are Mission Vision & Core Values of Pharvaris Company?

Pharvaris Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

What are the foundational statements guiding Pharvaris; strategic direction;

Mission and vision statements are crucial for any business, offering purpose and direction. They guide decisions, align internal efforts, and communicate identity. For a clinical-stage biopharmaceutical company like Pharvaris, focused on rare diseases, these statements are vital for navigating a rapidly growing market.

The hereditary angioedema therapeutics market is expanding from $6.68 billion in 2024 to a projected $7.84 billion in 2025, a 17.3% CAGR. It is expected to reach $16.11 billion by 2029, growing at a 19.7% CAGR. Pharvaris;s mission, vision, and core values serve as its compass in this dynamic landscape, influencing research, market expansion, and corporate identity. These principles articulate Pharvaris;s commitment to addressing unmet medical needs and improving patient quality of life, as detailed in the Pharvaris BCG Matrix.

The Pharvaris mission focuses on developing innovative oral therapies for individuals with hereditary angioedema (HAE) and other bradykinin-mediated conditions. This includes addressing unmet needs in patient care by offering convenient treatment options. The company's commitment extends to improving the standard of care globally for those affected by these debilitating diseases.

Patient-Centric Innovation

Pharvaris prioritizes developing treatments that directly address patient needs, focusing on convenience and improved quality of life.

Oral Therapy Focus

The company specializes in oral bradykinin B2 receptor antagonists, aiming to provide alternatives to injectable therapies.

Addressing Unmet Needs

Pharvaris seeks to fill gaps in current treatment options for HAE and other related conditions.

Global Impact

The mission encompasses improving care for patients worldwide, regardless of their specific type of bradykinin-mediated angioedema.

Clinical Development

Ongoing pivotal Phase 3 studies, such as RAPIDe-3 and CHAPTER-3, demonstrate commitment to advancing new therapies.

Investment in R&D

Increased R&D expenses, reaching €30.9 million in Q1 2025, highlight significant investment in fulfilling their mission.

The Pharvaris mission is centered on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs and improve the standard of care for individuals living with HAE and other bradykinin-mediated diseases. This patient-centric approach is evident in their focus on convenient oral therapies. The company's ongoing pivotal Phase 3 studies, RAPIDe-3 for on-demand treatment and CHAPTER-3 for prophylactic treatment of HAE attacks with deucrictibant, directly support this mission. In Q1 2025, Pharvaris reported R&D expenses of €30.9 million, an increase from €18.5 million in Q1 2024, demonstrating their continued investment in clinical development to fulfill this mission. The company's efforts to expand deucrictibant's potential treatment opportunities beyond HAE type 1/2 to include AAE-C1INH further exemplify their dedication to addressing broad unmet needs within bradykinin-mediated angioedema. For a broader view of the market, consider the Competitors Landscape of Pharvaris.

Pharvaris SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The Pharvaris vision is to revolutionize hereditary angioedema (HAE) treatment by offering oral therapies that match the efficacy of injectables while providing superior tolerability. This ambitious vision extends to addressing all types of bradykinin-mediated angioedema, including acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), for which no approved therapies currently exist. This aligns with the Pharvaris vision for the future of healthcare.

Pharvaris Mission

The Pharvaris mission focuses on developing innovative oral therapies for rare diseases, particularly those mediated by bradykinin, to improve patient lives.

Patient-Centric Approach

Pharvaris demonstrates a strong commitment to patients, aiming to address unmet medical needs with convenient and effective treatments.

Innovation Driven

The company's strategic mission emphasizes innovation, particularly in developing oral therapies that offer advantages over existing injectable treatments.

Scientific Rigor

Pharvaris maintains high scientific standards in its research and development, ensuring robust clinical trials and data integrity.

Ethical Conduct

Pharvaris operates with strong ethical core values, ensuring transparency and integrity in all business practices and patient interactions.

Team Collaboration

The company fosters a collaborative environment, valuing diverse perspectives to achieve its ambitious goals in rare disease treatment.

Pharvaris's vision is to provide injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy to prevent and treat HAE attacks. This vision is supported by their progress in clinical development, with deucrictibant in pivotal Phase 3 studies. Topline data for the RAPIDe-3 study is expected in Q4 2025, and for the CHAPTER-3 study in 2H 2026. The company's financial position, with €236 million in cash and cash equivalents as of March 31, 2025, provides a cash runway into Q3 2026, supporting their aggressive clinical development plans. The hereditary angioedema therapeutics market is projected to reach $16.11 billion by 2029, highlighting the market potential for Pharvaris's oral therapies. Understanding Pharvaris mission and vision reveals their commitment to patients and innovation. For more insights into their strategic approach, explore the Growth Strategy of Pharvaris.

Pharvaris PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Pharvaris operates with a set of core values that underpin its corporate culture and guide its operations. These principles emphasize deep empathy for patients, fostering trust, ensuring rigorous scientific inquiry, and promoting open contribution from all team members.

The company's core values, while not always explicitly listed as four distinct points in public statements, can be distilled into considering others carefully, leading with trust, ensuring rigor and diversity of thought, and contributing freely. These values collectively shape the Pharvaris company culture and its approach to developing treatments for rare diseases.

Considering Others Carefully

This Pharvaris core value emphasizes deep empathy and consideration for all individuals impacted by the company's mission, particularly patients. It drives the development of patient-centric therapies like deucrictibant, aiming for convenience and improved quality of life.

Leading with Trust

This value promotes an environment of trust and respect for expertise, experience, and decisions made across the organization. It encourages rigorous, well-informed decision-making based on robust critical thinking and transparent data reporting.

Ensuring Rigor and Diversity of Thought

This Pharvaris core value prioritizes thoroughness, critical thinking, pragmatism, and welcoming diverse perspectives in decision-making. It is evident in their comprehensive clinical development programs and pursuit of innovative regulatory pathways.

Contributing Freely

This value highlights the freedom employees have to contribute their ideas and insights, along with the responsibility to speak up. It supports a collaborative and open environment, fostering proactive engagement and problem-solving.

These Pharvaris core values collectively define the company's identity and commitment to patients. To understand how these values translate into strategic decisions, explore how the Pharvaris mission and vision influence the company's strategic direction in the next chapter. You can also learn more about the Owners & Shareholders of Pharvaris.

Pharvaris Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

A company's mission and vision are crucial in shaping its strategic decisions, providing a clear direction for growth and development. These guiding principles ensure that all actions and investments align with the organization's ultimate purpose and aspirations.

Pharvaris's Strategic Compass: Mission and Vision

Pharvaris's mission to address unmet needs and improve the standard of care for bradykinin-mediated diseases directly influences its strategic focus on developing novel oral therapies.

• The vision of providing injectable-like efficacy with oral convenience guides product development.
• Strategic decisions are aligned with improving patient quality of life.
• Investment in clinical development of deucrictibant is a direct outcome of the mission.
• Pipeline expansion into new indications reflects a commitment to broader unmet needs.

Mission in Action: Deucrictibant Development

The company's mission to address unmet needs is evident in the simultaneous progression of two pivotal Phase 3 clinical studies for deucrictibant, targeting both on-demand and prophylactic treatment of HAE attacks.

Vision for Patient Care

Pharvaris's vision for 'injectable-like efficacy and placebo-like tolerability with the convenience of an oral therapy' directly informs the design and goals of its clinical trials.

Financial Commitment to Strategy

In Q1 2025, R&D expenses increased to €30.9 million from €18.5 million in Q1 2024, demonstrating significant financial commitment to advancing their mission-driven pipeline.

Pipeline Expansion Strategy

The strategic decision to expand into acquired angioedema due to C1 inhibitor deficiency in 2025, a condition with no approved therapies, directly aligns with the mission to address broader unmet needs.

Measurable Success Metrics

Achieving target enrollment in the RAPIDe-3 study in March 2025 serves as a measurable success metric, reinforcing confidence in clinical timelines and strategic execution.

Long-Term Planning and Values

The company's long-term planning consistently evaluates opportunities to expand treatment options and address broader indications, guided by a commitment to patient-centric research and improving quality of life, as detailed in the Mission, Vision & Core Values of Pharvaris.

These principles shape day-to-day operations and long-term planning, ensuring consistent progress towards their goals. Continue reading to explore core improvements to company's mission and vision.

Pharvaris Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Enhancing Pharvaris's mission and vision involves a strategic focus on patient access and sustainability. By explicitly incorporating these elements, the company can better align with global healthcare trends and stakeholder expectations.

Integrate Patient Access and Affordability

Explicitly stating a commitment to patient access and affordability, especially for rare disease therapies, would strengthen the company's purpose. The hereditary angioedema therapeutics market is projected to reach $16.11 billion by 2029, highlighting the importance of global access initiatives.

Emphasize Global Accessibility and Social Impact

A vision statement that includes enabling widespread access to transformative therapies for bradykinin-mediated diseases would underscore a commitment to social impact. This aligns with growing ESG considerations, as patient groups increasingly survey pharmaceutical companies on their performance in this area.

Incorporate Sustainability Commitments

Acknowledging a commitment to sustainable innovation within the mission or vision could enhance appeal to environmentally conscious stakeholders. This could involve adapting the mission to include developing therapies through sustainable and responsible practices.

Address Emerging Technologies and Future Adaptability

Refining statements to acknowledge advancements like gene therapy and personalized medicine would position the company for future market shifts. This proactive approach ensures long-term relevance and impact in a dynamic healthcare landscape, building upon the Brief History of Pharvaris.